Journal of Biological Sciences1727-30481812-5719Asian Network for Scientific Information10.3923/jbs.2010.767.772Brucella abortus 544 based on a Combination of Fusion Proteins, Human Serum Albumin and Brucella abortus Lipopolysaccharides]]>PakzadI. RezaeeA. RasaeeM.J. HosseiniA.Z. TabbaraeeB. GhafurianS. AbdulamirA.S. Abu BakarF. RaftariM. 82010108Lipopolysaccharide (LPS) of Brucella abortus is an essential component for developing the subunit vaccine against brucellosis. B. abortus LPS was extracted by n-butanol, purified by ultracentrifugation and detoxified by alkaline treatment. Pyrogenicity and toxicity of B. abortus LPS and detoxifiedLPS (D-LPS) were analyzed and compared with LPS of E. coli. Different groups of mice were immunized intraperitoneally with purified B. abortus LPS, D-LPS, a combination of LPS with human serum albumin (LPS-HSA) and B. abortus S19 bacteria; besides, control mice were inoculated with sterile saline. Two doses of vaccine were given 4 weeks apart. Mice were challenged intraperitoneally with virulent B. abortus 544 strain 4 weeks after the second dose of vaccine. Sera and spleens of mice were harvested 4 weeks after challenge. LPS-B. abortus was 10,000-fold less potent in LAL test and 100-fold less potent in eliciting fever in rabbits than in E. coli LPS. And D-LPS was very less potent in LAL test and eliciting fever in rabbits ordinary LPS. The antibody titer of anti-LPS immunoglobulin G (IgG) was higher than D-LPS. However, mice immunized with either LPS, D-LPS or LPS-HSA vaccines showed a significant protection against infection of the spleen (p<0.01). There was no significant difference between mice immunized with LPS and D-LPS in terms of protection (p<0.99). Therefore, it was concluded that D-LPS and LPS-HSA for B. abortus can be used as safer and more potent vaccines than ordinary LPS-B. abortus vaccine.]]>Al-Mariri, A., A. Tibor, P. Mertens, X. De Bolle and P. Michel et al.,2001Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.]]>6948164822Apicella, M.A., J.M. Griffiss and H. Schneider,1994235242252Bhattacharjee, A.K., M.J. Izadjoo, W.D. Zollinger, M.P. Nikolich and D.L Hoover,2006Brucella melitensis lipopolysaccharide subunit vaccine.]]>7458205825Bhattacharjee, A.K., L. van de Verg, M.J. Izadjoo, L. Yuan, T.L. Hadfield, W.D. Zollinger and D.L. Hoover,2002Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein.]]>7033243329Cloeckaert, A., I. Jacques, P. de Wergifosse, G. Dubray and J.N. Limet,1992Brucella melitensis or Brucella abortus in mice with immunoglobulin G (IgG), IgA and IgM monoclonal antibodies specific for a common epitope shared by the brucella A and M smooth lipopolysaccharides.]]>60312315Cloeckaert, A., M.S. Zygmunt, G. Dubray and J.N. Limet,1993Brucella melitensis strain B115.]]>13915511556Corbeil, L.B., K. Blau, T.J. Inzana, K.H. Nielsen, R.H. Jacobson, R.R. Corbeil and A.J. Winter,1988Brucella abortus by bovine serum.]]>5632513261David, S.A.,19991999pp: 413-422pp: 413-422Edmonds, M.D., A. Cloeckaert and P.H. Elzer,2002Brucella melitensis and Brucella ovis.]]>88205221Elzer, P.H., F.M. Enright, J.R. McQuiston, S.M. Boyle and G.G. Schurig,1998Brucella melitensis in pregnant goats.]]>64259260Elzer, P.H., R.H. Jacobson, S.M. Jones, K.H. Nielsen, J.T. Douglas, A.J. Winter,1994Brucella abortus in BALB/c mice at successive periods after infection: Variation between virulent strain 2308 and attenuated vaccine strain 19.]]>82651658Engvall, E. and P. Perlmann,1972109129135Goldstein, J., T. Hoffman, C. Frasch, E.F. Lizzio and P.R. Beining et al.,1992Brucella abortus is less toxic than that from Escherichia coli, suggesting the possible use of B. abortus or LPS from B. abortus as a carrier in vaccines.]]>6013851389Jacques, I., V. Olivier-Bernardin and G. Dubray,19919896900Jones, S.M. and A.J. Winter,1992Brucella abortus in normal and gamma interferon-activated murine peritoneal macrophages.]]>6030113014McQuiston, J.R., R. Vemulapalli, T.J. Inzana, G.G. Schurig and N. Sriranganathan et al.,1999Brucella abortus and its effect on lipopolysaccharide composition and virulence.]]>6738303835Oliveira, S.C. and G.A. Splitter,1996Brucella abortus infection.]]>14959962Pappagianis, D., S.S. Elberg and D. Crouch,1966Brucella melitensis in humans.]]>842131Poelstra, K., W.W. Bakker, P.A. Klok, M.J. Hardonk and D.K. Meijer,199776319327Spink, W.W., J.W. Hall, J. Finstad and E. Mallet,1962Brucella organisms results of a safety test in humans.]]>26409419Tsai, C.M. and C.E. Frasch,1982119115119Vemulapalli, R., Y. He, S. Cravero, N. Sriranganathan, S.M. Boyle and G.G. Schurig,2000Brucella abortus strain RB51.]]>6832863289Winter, A.J., G.E. Rowe, J.R. Duncan, M.J. Eis, J. Widom, B. Ganem and B. Morien,1988Brucella abortus in mice.]]>5628082817Winter, A.J., G.G. Schurig, S.M. Boyle, N. Sriranganathan and J.S. Bevins et al.,1996Brucella melitensis and Brucella suis biovar 4.]]>57677683Pakzad, I., A. Rezaee, M.J. Rasaee, A.Z. Hossieni, B. Tabbaraee and A. Kazemnejad,2010Brucella abortus 544 challenge by vaccination with combination of recombinant human serum albumin-l7/l12 (Brucella abortus ribosomal protein) and lipopolysaccharide.]]>69512Jamalan, M., S.K. Ardestani, M. Zeinali, N. Mosaveri and M.T. Mohammad,2010Brucella abortus lipopolysaccharide as an adjuvant for tuberculin PPD.]]>6145152